Genmab — September 2020
-
Should this occur, Janssen will pay Genmab a USD 150 million option exercise fee and up to USD 125 million in development milestones, as well as a flat royalty rate of 20% on sales of HexaBody-CD38 until a specified time in 2031, followed by 13-20% tiered royalties on sales thereafter.
-
Ditto.
-
Enig Solsen. Næsten 1/3 del af salget.
-
Hvordan er udviklingen dag til dag i salget?
-
Cami solids trial adds a combi arm with Pembrolizumab https://clinicaltrials.gov/ct2/history/NCT03621982?A=10&B=11&C=merged#StudyPageTop
(if that is still of interest...) -
Borsen -Stærke salgstal for Genmabs kræftsællert: Trods modvind fastholder Citi højt kursmål https://borsen.dk/nyheder/virksomheder/midt-i-modvind-kommer-staerke-salgstal-for-genmab
-
Det bliver interessant at se hvad der sker med kursen når USA åbner.
-
Det lyder overvejende sandsynligt
Du er lidt af en spåmand 
-
Det virker som om nogle i markedet mener Genmab skal bære hele byrden af JNJs betaling til HALO. Men når jeg læser følgende sætning,så vil jeg mene det er max. en 1/5-del af HALO betalingen som Genmab skal bære: Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab’s share of Janssen’s royalty payments to Halozyme for the second quarter of 2020.
-
Da Genmab får max 20% i royalties, så kan Genmabs andel af skaden vel ikke overstige en 1/5-del?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind